Capricor Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Capricor Therapeutics, Inc.
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Capricor Inc.
- Nile Therapeutics